BC Innovations | Jul 24, 2018
Distillery Therapeutics


INDICATION: Colorectal cancer Cell culture and mouse studies suggest inhibiting RAD52 could help treat FANCM-deficient colorectal cancer. In a FANCM-knockout human colorectal cancer cell line, an shRNA targeting RAD52 encoded in a retroviral or lentiviral...
BC Innovations | Dec 8, 2017
Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
BC Innovations | Dec 17, 2015
Distillery Therapeutics

Therapeutics: RAD52 homolog (RAD52); breast cancer 1 early onset (BRCA1); BRCA2

Cancer INDICATION: Cancer; leukemia In vitro studies identified 6-hydroxy-DL-dopa as an allosteric inhibitor of RAD52 that could help treat BRCA1- or BRCA2-deficient cancers and leukemias. In a high throughput screen of a library of drug-like...
BC Innovations | Jan 6, 2011
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Breast cancer 2 early onset (BRCA2); RAD52 homolog (RAD52) In vitro studies suggest that inactivating RAD52 could help treat BRCA2-defective tumors. Small hairpin RNA...
Items per page:
1 - 4 of 4